Exelixis raises $71.8 million through stock offering

South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.

Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/
Previous story
Con-way Inc. awards 45 college scholarships
Next story
Rich suburb to save big bucks

Just Posted

Union threatens legal action after Police Commission expands use-of-force policy

San Francisco’s police union is pursuing legal action after the Police Commission… Continue reading

Restorative art on the inside and out

Curator Ericka Scott organizes exhibition of works by prisoners

City Attorney seeks to recoup ‘illegal profits’ gained by Walter Wong through city contracts

San Francisco will seek to recover “illegal profits” gained by well-known permit… Continue reading

SF Police Commission votes to expand use-of-force policy

Decision to bypass union negotiations could set stage for litigation

Free Muni for Youth program expansion halted by SFMTA budget crisis

Low- and moderate-income kids can still travel for free

Most Read